In a nutshell This study investigated the individual risk of ischemic heart disease and stroke through age 50 in 5-year survivors of childhood cancer. The authors concluded that these conditions can be reasonably predicted using information available after childhood cancer therapy. Some background For the 400,000 childhood cancer survivors in the...Read More
Hodgkin’s lymphoma Posts on Medivizor
Thirty-eight states in the US have passed “Right To Try” laws. These are laws that are created to give terminally ill patients who have run out of options access to experimental drugs that have not completed the FDA approval process. There is an effort underway to pass this type of legislation on a federal level. On February 8, the #LCSM (Lung...Read More
Do two cycles of stem cell therapy lead to longer progression free survival in relapsed or refractory HL patients?
In a nutshell This study determined if progression-free survival (time from treatment before disease progression) could be improved in patients with relapsed or refractory Hodgkin’s lymphoma (HL) who received two cycles (tandem) of autologous hematopoietic stem cell transplantation (AHSCT). This study concluded that tandem AHSCT appears effective...Read More
In a nutshell The current paper reviews the development of new therapies for Hodgkin's lymphoma (HL), including combination chemotherapy and immunotherapies. Some background Hodgkin’s lymphoma (HL) comprises 10% of new lymphoma cases in the U.S., with 21% of these occurring in adolescents. Thanks to advancements in treatment, mortality rates...Read More
In a nutshell This study looked at the risk of developing breast cancer while on hormone replacement therapy for female patients who were treated with radiation for Hodgkin lymphoma. The authors concluded that radiation therapy significantly increased the risk of developing breast cancer, and hormone replacement therapy did not significantly increase the...Read More
In a nutshell This study looked at the long term outcomes for patients with Hodgkin lymphoma who were treated with radiation therapy. The study concluded that patients treated with radiation therapy had better outcomes compared to patients not treated with radiation therapy. Some background Patients with Hodgkin lymphoma (HL) generally have good...Read More
Does liposomal doxorubicin improve heart side effects in lymphoma patients compared to conventional doxorubicin?
In a nutshell This study investigated the impact of liposomal doxorubicin (Adriamycin) on cardiac side effects in lymphoma patients compared to conventional doxorubicin. The study suggested that liposomal doxorubicin can reduce cardiac effects and still be an effective therapy, particularly for patients at high risk for anthracycline-induced...Read More
Does PET/CT scanning after one ABVD cycle better predict treatment outcomes than scanning after two cycles (iPET2)?
In a nutshell This study analyzed PET/CT scans from new Hodgkin’s lymphoma patients after one (iPET1) or two (iPET2) cycles of ABVD chemotherapy. The study concluded that iPET2 is better than iPET1 at predicting ABVD outcomes in HL patients. Some background Interem PET/CT scanning is used to guide early treatment for new Hodgkin’s...Read More
What are the long-term outcomes for early-stage HL patients who received radiotherapy alone or combined with chemotherapy?
In a nutshell This study determined long-term risk of death from all causes using data from 1,541 early-stage (stage 1-2) Hodgkin’s lymphoma (HL) patients who received radiotherapy (RT) alone or RT with chemotherapy. This study concluded that this risk was significantly lower for patients treated in the most recent era of radiation therapy thanks...Read More
What are the outcomes for advanced HL patients receiving intensified BEACOPP chemotherapy after ABVD chemotherapy?
In a nutshell This study investigated the outcomes of advanced-stage classical Hodgkin’s lymphoma (HL) patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by escalated (higher dose) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) chemotherapy...Read More
What are the real-world outcomes for ASCT-ineligible patients with refractory or relapsed HL who are given brentuximab vedotin?
In a nutshell This study determined the real-world outcomes for patients with relapsed or refractory Hodgkin’s lymphoma (rrHL) who were given brentuximab vedotin (Adcetris) due to ineligibility for autologous stem cell transplant (ASCT). The study concluded that brentuximab vedotin is feasible and effective in patients with rrHL who are...Read More
In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...Read More